Saturday, 17 June 2017 791 selected for outcome analyses. Among seropositive patients, both LDA and remission were less frequently achieved in case of RF-positivity. Relevantly, in ACPA-positive patients (n=273), the co-occurrence of RF dose-dependently influenced clinical outcomes. After 6 months of treatment, LDA and disease remission were achieved respectively by 69.6% and 47.8% of single ACPApositive, 68.8% and 37.5% of ACPA-positive RF-low, and 57% and 27.6% of ACPA-positive RF-high patients (chi-square for trend p=0.18 for LDA, p=0.05 for remission). After adjusting for confounders (age, gender, symptoms' duration, baseline disease activity, use of prednisone, recruitment period), high levels of RF independently predicted failure to achieve LDA with an HR (95% CI) of 0.61 (0.39 to 0.95) and failure to achieve remission with an HR (95% CI) of 0.63 (0.35 to 0.99) (Figure 1 ). In contrast, ACPA levels did not show any significant predictive value, neither for thresholds of >3 ULN nor of >100 U.
Background: The HONOR (humira discontinuation without functional and radiographic damage following sustained remission) study was designed to investigate the possibility of patients discontinuing adalimumab (ADA) therapy for 1 year without flaring (DAS28-ESR ≥3.2). 14-3-3η is a mechanistic serum marker that is modifiable over the disease course, does not correlate with CRP and is a predictor of radiographic progression even in patients who achieve clinical remission. The uncoupling of inflammation and joint damage processes in RA underscores a risk of premature discontinuation of biologic treatment when aiming to achieve sustained remission. Serum markers that could indicate which patients are at risk of flare and continued joint damage despite clinical remission are highly desirable. Objectives: In this study, serum 14-3-3η was investigated as a predictor of joint damage and flares in the HONOR cohort. Methods: Serum 14-3-3η levels were measured in 62 Japanese patients, 51 of which were from the HONOR study at baseline, 1-year after treatment initiation, at discontinuation and at the time of flare. Of the 62 patients, 46 (74%) patients achieved sustained drug-free remission up to 1 year following ADA discontinuation. Sharp van der Heidje (SHS) scores were available at therapy initiation, discontinuation, and at 52 weeks following. Relationships between continuous variables were assessed using uni-and multi-variable Gaussian linear regression models and logistic regression. Results: At baseline and discontinuation, median (QR) 14-3-3η levels were 0.28 ng/ml (0.07-2.11) and 0.22 ng/ml (0.04-1.28) respectively, with 26 (59%) of 44 and 29 (54%) of 54 patients being positive (≥0.19 ng/ml) at the corresponding time-points. Paired t-test revealed that levels of 14-3-3η were significantly different between baseline and discontinuation, p=0.030. Level of 14-3-3η at baseline was positively associated with SHS at 12 months and at the time of flare, p=0.038. Bivariable modeling revealed that baseline 14-3-3η together with the change in 14-3-3η had a significant interacting effect on SHS at 12 months and the time of flare, p=0.02. Higher baseline 14-3-3η levels together with an increase in levels at the time of discontinuation was strongly associated with an increased SHS. Adding CRP, flare, sustained remission through 12 months, MTX dose at initiation and at ADA discontinuation did not improve predictive effects of 14-3-3η with SHS. Baseline 14-3-3η levels alone was not associated with flares at 12 months (p=0.15) however when combined with CRP, a significant interaction was present (p=0.03). Specifically, patients with a low CRP, and a high 14-3-3η level had a higher likelihood of flaring versus those with a low 14-3-3η, 22% versus 12%. Conclusions: Baseline 14-3-3η and increases in its levels are associated with worse radiographic outcomes in patients who achieve clinical remission and discontinue ADA. To reduce the risk of flare in patients who are candidates for discontinuation of ADA, CRP and 14-3-3η measurements should be considered in combination as markers of flare prediction. Background: Treat-to-target (T2T) approach suggests using a composite index when following patients with rheumatoid arthritis (RA) without identifying which one to use. Objectives: In this prospective study we aimed to compare the accuracy of different indices for RA patients in remission taking Ultrasound Global Synovitis Score (GLOESS) as a gold standard and their predictive value for flares in 2 years. Methods: RA patients who were considered to be in clinical remission according to the clinician were recruited. Disease activity was assessed using DAS28-CRP, CDAI, SDAI and RAPID-3 and 38 joints per patient were scanned by US and scored according to GLOESS. The total GLOESS scores were calculated for 38 joints and also for 28 joints by excluding the MTP joints. The number of joints with ≥2 GLOESS was calculated. Flare data was collected in 3 subsequent visits in the following 2 years, whenever available. Results: Ninety-six consecutive patients (80.2% females) were recruited. Patients were more frequently categorized as being in remission using DAS28 (80%) compared to CDAI (50%), SDAI (45.2%) and RAPID 3 (37.5%). Patients that were in remission according to CDAI had lower GLOESS scores on 28 joints (p=0.05) and had less joints with ≥2 signals (p=0.04) ( Objectives: To investigate the association of high baseline MMP-3 serum levels with hands and feet joints structural damage progression, estimated by ultrasonography (US), in patients with early, treatment "naïve" RA without X-ray visible erosions. Methods: Sixty-three pts. (9 males and 54 females; mean age 53.4 yrs 21-81±14.1) with early RA (EULAR/ACR 2010 criteria) and symptom duration of ≤12 months (mean duration of 3.8 months) had baseline serum MMP-3 levels tested. Patients had been DMARDs/glucocorticoid naïve, without visible X-ray erosions at the study entry. The subsequent structural joints damages, that were estimated by high frequency linear probe by ESAOTE My Lab 70 machine, as well as clinical markers of disease activity, in the first 2 years were followed. The presence of bone erosion was analyzed at the wrist, MCP2 and MCP5 joints of both hands, as well as at MTP5 joints according to OMERACT US group definition. In order to estimate progression of preexisting erosion the total volume (TV) of bone erosion were calculated by multiplying three diameters (mm): a-the length of erosion; diameter b-the width and diameter c-the depth of erosion. Anova statistical method was performed in data processing. Results: 46 pts. had basal serum MMP-3 level higher than normal (MMP-3 positive). The 504 joints were assessed summary by US on each visit. The 122 bone erosions in total (1.9 per patient) were depicted at baseline and 213 bone erosions (4.3 per patient) at follow-up visit in whole group. After 24 months MMP3 positive pts. had significantly higher total number of US erosions than MMP-3 negative (3.8 vs. 2.4, p=0.039). The total volume of bone erosion (mm 3 ) was higher in MMP-3 positive than MMP-3 negative pts. after 24 months of treatment, but without statistical significance (18.6 vs. 8.9, p=0.07). MMP-3 positive pts. had a significantly higher value of ESR, CRP and DAS28 than MMP-3 negative pts. at the baseline visit (53.6 vs.25.9, p=0.002; 36.6 vs. 9.5, p=0.005; 6.0 vs. 4.8, p=0.002, respectively) . All of those parameters were significantly decreased after 24 months in a group of MMP-3 positive compared to MMP-3 negative pts. (p=0.009, p=0.021, p=0.028, respectively). Conclusions: After 2-year of follow-up, US assessment showed a significantly higher number of new bone erosions in patients with early, treatment "naïve" RA and baseline MMP3 levels higher than normal (MMP3 positive) compared to patients with normal baseline levels of MMP3, as well as a biger TV of bone erosions but not statistically significant. The parameters of RA activity (ESR, CRP, DAS28) significantly correlated with baseline MMP-3 levels of higher than normal. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.4002 
